IS5715A - Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni - Google Patents

Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni

Info

Publication number
IS5715A
IS5715A IS5715A IS5715A IS5715A IS 5715 A IS5715 A IS 5715A IS 5715 A IS5715 A IS 5715A IS 5715 A IS5715 A IS 5715A IS 5715 A IS5715 A IS 5715A
Authority
IS
Iceland
Prior art keywords
carboxyamino
tetrahydroquinoline
substituted
construction
Prior art date
Application number
IS5715A
Other languages
English (en)
Icelandic (is)
Inventor
Burns Damon David
Wayne Dugger Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5715A publication Critical patent/IS5715A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5715A 1999-11-30 2000-11-17 Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni IS5715A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
IS5715A true IS5715A (is) 2001-05-31

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5715A IS5715A (is) 1999-11-30 2000-11-17 Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni

Country Status (44)

Country Link
US (1) US6313142B1 (enExample)
EP (1) EP1125929B1 (enExample)
JP (1) JP3579345B2 (enExample)
KR (1) KR100408177B1 (enExample)
CN (1) CN1173953C (enExample)
AP (1) AP2000002011A0 (enExample)
AR (1) AR029775A1 (enExample)
AT (1) ATE315028T1 (enExample)
AU (1) AU784694B2 (enExample)
BG (1) BG105009A (enExample)
BR (1) BR0005636A (enExample)
CA (1) CA2327029C (enExample)
CO (1) CO5261552A1 (enExample)
CY (1) CY1104989T1 (enExample)
CZ (1) CZ20004407A3 (enExample)
DE (1) DE60025317T2 (enExample)
DK (1) DK1125929T3 (enExample)
DZ (1) DZ3079A1 (enExample)
EA (1) EA003668B1 (enExample)
EE (1) EE200000659A (enExample)
ES (1) ES2254109T3 (enExample)
GE (1) GEP20022798B (enExample)
GT (1) GT200000190A (enExample)
HN (1) HN2000000203A (enExample)
HR (1) HRP20000804A2 (enExample)
HU (1) HUP0004747A3 (enExample)
ID (1) ID28489A (enExample)
IL (1) IL139849A (enExample)
IS (1) IS5715A (enExample)
MA (1) MA25223A1 (enExample)
NO (1) NO20006039L (enExample)
NZ (1) NZ508509A (enExample)
OA (1) OA11494A (enExample)
PA (1) PA8503801A1 (enExample)
PE (1) PE20010913A1 (enExample)
PL (1) PL344208A1 (enExample)
SG (1) SG102603A1 (enExample)
SK (1) SK17792000A3 (enExample)
TN (1) TNSN00230A1 (enExample)
TW (1) TW591016B (enExample)
UA (1) UA65615C2 (enExample)
UY (1) UY26451A1 (enExample)
YU (1) YU71500A (enExample)
ZA (1) ZA200006947B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
BR0215240A (pt) * 2001-12-19 2004-10-26 Atherogenics Inc Derivados de calcona e seu uso no tratamento de doenças
ATE410521T1 (de) * 2002-04-11 2008-10-15 Roar Holding Llc Ex-vivo-verfahren zur bestimmung der cetp- aktivität und der wirksamkeit der behandlung von herzerkrankungen
EA011385B1 (ru) * 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
WO2004078730A2 (en) * 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
ATE534381T1 (de) * 2003-03-17 2011-12-15 Japan Tobacco Inc Pharmazeutische cetp-inhibitor-zusammensetzungen
JP2006520810A (ja) * 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
ES2332051T3 (es) * 2003-10-08 2010-01-25 Eli Lilly And Company Compuestos y procedimientos para tratar dislipidemia.
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
EP1861372A1 (en) * 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
EP4551567A1 (en) 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (enExample) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
GT200000190A (es) 2002-04-27
UA65615C2 (uk) 2004-04-15
DK1125929T3 (da) 2006-04-03
EA003668B1 (ru) 2003-08-28
OA11494A (en) 2004-05-07
NO20006039D0 (no) 2000-11-29
DZ3079A1 (fr) 2004-10-24
UY26451A1 (es) 2001-06-29
ID28489A (id) 2001-05-31
PL344208A1 (en) 2001-06-04
PE20010913A1 (es) 2001-09-10
CA2327029A1 (en) 2001-05-30
AP2000002011A0 (en) 2000-12-31
HUP0004747A3 (en) 2002-12-28
BR0005636A (pt) 2001-07-17
CN1302800A (zh) 2001-07-11
NO20006039L (no) 2001-05-31
HK1038007A1 (en) 2002-03-01
PA8503801A1 (es) 2002-07-30
EP1125929A1 (en) 2001-08-22
BG105009A (en) 2001-11-30
YU71500A (sh) 2003-02-28
IL139849A (en) 2006-10-31
DE60025317D1 (de) 2006-03-30
EA200001129A2 (ru) 2001-06-25
DE60025317T2 (de) 2006-08-03
CA2327029C (en) 2005-08-09
CZ20004407A3 (cs) 2002-06-12
AU7178900A (en) 2001-05-31
AR029775A1 (es) 2003-07-16
JP3579345B2 (ja) 2004-10-20
AU784694B2 (en) 2006-06-01
JP2001163859A (ja) 2001-06-19
HN2000000203A (es) 2001-06-13
HUP0004747A2 (hu) 2001-10-28
EA200001129A3 (ru) 2001-10-22
SG102603A1 (en) 2004-03-26
TNSN00230A1 (fr) 2005-11-10
EP1125929B1 (en) 2006-01-04
NZ508509A (en) 2001-06-29
HU0004747D0 (enExample) 2001-02-28
MA25223A1 (fr) 2001-07-02
CN1173953C (zh) 2004-11-03
GEP20022798B (en) 2002-09-25
ES2254109T3 (es) 2006-06-16
CY1104989T1 (el) 2010-03-03
CO5261552A1 (es) 2003-03-31
SK17792000A3 (sk) 2002-10-08
ATE315028T1 (de) 2006-02-15
TW591016B (en) 2004-06-11
EE200000659A (et) 2001-08-15
KR20010052012A (ko) 2001-06-25
IL139849A0 (en) 2002-02-10
KR100408177B1 (ko) 2003-12-01
US6313142B1 (en) 2001-11-06
ZA200006947B (en) 2002-05-27
HRP20000804A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
IS5715A (is) Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni
IS2223B (is) Aðferð til framleiðslu á 5-sýanóþalíði
FI991470L (fi) Yhteyksien valintamenetelmä
DK1140935T3 (da) 1,2-anellerede quinolinderivater
IS2556B (is) Nýjar kínasólín afleiður.
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
ID24790A (id) Proses untuk memfraksionasi dibutena
IS2261B (is) Aðferð til framleiðslu á 5-sýanóþalíði
ID25682A (id) Metode untuk melelehkan kaca
IT1319251B1 (it) Metodo per la preparazione di 5-carbossiftalide.
ID26478A (id) Penggambaran kelima macam langkah produksi
IS5600A (is) Aðferð til framleiðslu á vernduðu 4-amínómetýl-pýrrólidín-3-óni.
ITBO990359A0 (it) Elettromandrino .
DE60029755D1 (de) Congawandschutz.
TR199800403A3 (tr) a-Bromo-laktam türevlerinin hazirlanmasi için yöntem.
FI19992215A7 (fi) Kalanterointimenetelmä
ITBO990358A0 (it) Elettromandrino .
DE50005753D1 (de) Montageverfahren
DE69942673D1 (de) Bedienungseinrichtung
IS5212A (is) Bætt aðferð til framleiðslu á pýrazólópýrimidínónafleiðu
TR199801514A3 (tr) N-Piruvil-L-Prolin üretimi için yöntem.
NO20005743L (no) Fremgangsmåte til fremstilling av 4,5-epoksymorfinan-6- glukuronider
FI991413A7 (fi) Yhteyden pystytysmenetelmä
ITMI991128A1 (it) Procedimento per il recupero di riboflavina.
ES1044838Y (es) Friegasuelos.